Pharmaceutical industry regulation undermines NICE drugs appraisal work

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

From Journal of the Royal Society of Medicine

Government policies that support UK pharmaceutical science and enhance export income are costing the NHS millions and undermine the National Institute for Health and Care Excellence. In this article health economists describe an inflationary regulatory system that lacks accountability, is not evidence-based and subverts the efficiency of the technology appraisal work carried out by NICE, a target of pharmaceutical industry hostility since it was established in 1999.

Professor Maynard concludes: “Government continues to subvert the efficiency of technology appraisal work carried out by NICE in order to subsidise industry. Does this benefit the UK taxpayer and NHS patients? Or does government tacitly wish to tax the NHS with high pharmaceutical prices of sometimes inefficient drugs and, in so doing, increase the wealth of industry?”

Read this article for free

Article details
Alan Maynard and Karen Bloor
Regulation of the pharmaceutical industry: promoting health or protecting wealth?
J R Soc Med 0141076814568299, first published on April 28, 2015 doi:10.1177/0141076814568299

 

 

     
This entry was posted in Medicine, SAGE Insight and tagged , , , . Bookmark the permalink.

Leave a Reply